Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic inflammatory diseases with overlapping features. Mepolizumab, a humanized mAb targeting IL-5, has been approved for treatment of both conditions. However, real-world data on its cl...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Michael E. Wechsler, MD, Anna Kovalszki, MD, Brian Stone, MD, Jared Silver, MD, PhD, Lior Seluk, MD, Jeremiah Hwee, PhD, Lynn Huynh, MPH, MBA, DrPH, Wilson da Costa Junior, MD, PhD, Shuang Wang, PhD, Mei Sheng Duh, ScD, William McCann, MD, Amy G. Edgecomb, PharmD, MPH
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-07-01
Serija:	Journal of Allergy and Clinical Immunology: Global
Teme:	Eosinophilic granulomatosis with polyangiitis hypereosinophilic syndrome mepolizumab oral corticosteroids clinical outcomes end-organ manifestations
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2772829326000573
Oznake:	Označite Brez oznak, prvi označite!